Search

everythinglearnresearchcommunity

for

Search:↓

5-alpha reductase inhibitors, like finasteride and dutasteride, are used for prostate issues, hair loss, and excessive hair growth, may help with COVID-19, but can cause sexual and mental health side effects, and their use in preventing prostate cancer needs more examination.

Using 5-alpha reductase inhibitors may lower prostate cancer risk in people with androgenetic alopecia.

A new drug, dutasteride, is at least as effective as the older drug, finasteride, for treating enlarged prostate and may have additional uses.

5-ARI therapy may help prevent prostate cancer progression.

New treatments for prostate cancer are less toxic and show promise, but more research is needed to enhance their effectiveness and reduce side effects.

Finasteride may help prevent prostate cancer.

5-alpha reductase inhibitors may have additional effects on cancer, mental health, heart health, and hormone levels beyond treating prostate enlargement.

Aromatase inhibitors can cause various adverse reactions, so monitoring is crucial.

Inhibiting 5α-reductase can help reduce prostate cancer risk and improve treatment.

Too much AKR1C3 enzyme causes resistance to finasteride by increasing testosterone.

Men on 5-alpha-reductase inhibitors might have worse COVID-19 outcomes.

Finasteride increases CD8+ T cells in BPH tissues.

5-alpha-reductase inhibitors help treat urinary symptoms from an enlarged prostate.

Five-alpha reductase inhibitors, like finasteride and dutasteride, can treat enlarged prostates, improve urination, reduce need for prostate surgery, and lower the risk of prostate cancer, but may increase the risk of higher grade prostate cancer. They can also treat male pattern baldness.

Sorafenib often causes skin side effects, indicating effective cancer treatment.

5α-reductase inhibitors don't stop bladder cancer from developing or getting worse.

Over 30 potential cancer prevention treatments are being tested, with some showing promise in early research.

5α-reductase inhibitors and alpha-1 adrenergic antagonists together effectively treat benign prostatic hyperplasia, with long-term benefits.

The drugs finasteride and dutasteride reduce low-grade prostate cancers but may double the risk of high-grade cancers.

The combination of TACE and Donafenib is effective and tolerable for treating unresectable liver cancer.

Combining dutasteride or finasteride with an α1 blocker is more effective for managing BPH than using either alone.

Plant-based compounds may offer safer prostate cancer treatment with fewer side effects.

5ARIs like finasteride can help prevent prostate cancer and treat BPH, but guidelines should be updated to reflect this.

New cancer treatments are less harmful to hair but can still cause hair loss, color, shape, and growth changes.

Chemoprevention can significantly lower cancer risks and needs more research and collaboration.

5αR inhibitors help slow early prostate cancer cell growth, suggesting combined treatments are needed.

PROTACs offer a new, precise way to treat cancer by breaking down harmful proteins.

5-alpha reductase inhibitors can cause sexual, neurologic, endocrine, and cardiovascular side effects, but these are rare and usually stop after ending treatment.